MN 553 Advanced Pharmacology Unit 9 Quiz 2021 (Real quiz)
Question 1 point
Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
Question options:
A need to monitor drugs metabolized by 2D6 for toxicity
Increased dosages needed of drugs metabolized by 2D6, such as the selective
serotonin reuptake inhibitors
Decreased conversion of codeine to morphine by CYP 2D6
The need for lowered dosages of drugs, such as beta blockers
Question 1/1
2 point
Rifampin is a nonspecific CYP450 inducer that may: Question options:
Lead to toxic levels of rifampin and must be monitored closely
Cause toxic levels of drugs, such as oral contraceptives, when coadministered
Induce the metabolism of drugs, such as oral contraceptives, leading to
therapeutic failure
Cause nonspecific changes in drug metabolism
Question 1/1
3 point
Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
Question options:
Decreased therapeutic levels of quinidine
Increased therapeutic levels of quinidine
Decreased levels of a coadministered drug, such as digoxin, that requires
Pglycoprotein for absorption and elimination
Increased levels of a coadministered drug, such as digoxin, that requires
Pglycoprotein for absorption and elimination
Question 1/1
4 point
Warfarin resistance may be seen in patients with VCORC1 mutation,
leading to: Question options:
Toxic levels of warfarin building up
Decreased response to warfarin
Increased risk for significant drug interactions with warfarin
Less risk of drug interactions with warfarin
Question 1/1
5 point
, Pharmacogenetic testing is required by the U.S. Food and Drug
Administration prior to prescribing:
Question options:
Erythromycin
Digoxin
Cetuximab
Rifampin
Question 1/1
6 point
Carbamazepine has a Black Box Warning recommending testing for the
HLA-B*1502 allele in patients with Asian ancestry prior to starting
therapy due to: Question options:
Decreased effectiveness of carbamazepine in treating seizures in Asian
patients with the HLA-B*1502 allele
Increased risk for drug interactions in Asian patients with the HLA-B*1502
allele
Increased risk for Stevens-Johnson syndrome in Asian patients with
HLAB*1502 Allele
Patients who have the HLA-B*1502 allele being more likely to have a
resistance to carbamazepine
Question 1/1
7 point
A genetic variation in how the metabolite of the cancer drug irinotecan SN-38
is inactivated by the body may lead to: Question options:
Decreased effectiveness of irinotecan in the treatment of cancer
Increased adverse drug reactions, such as neutropenia
Delayed metabolism of the prodrug irinotecan into the active metabolite SN38
Increased concerns for irinotecan being carcinogenic
Question 1/1
8 point
Question 1 point
Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:
Question options:
A need to monitor drugs metabolized by 2D6 for toxicity
Increased dosages needed of drugs metabolized by 2D6, such as the selective
serotonin reuptake inhibitors
Decreased conversion of codeine to morphine by CYP 2D6
The need for lowered dosages of drugs, such as beta blockers
Question 1/1
2 point
Rifampin is a nonspecific CYP450 inducer that may: Question options:
Lead to toxic levels of rifampin and must be monitored closely
Cause toxic levels of drugs, such as oral contraceptives, when coadministered
Induce the metabolism of drugs, such as oral contraceptives, leading to
therapeutic failure
Cause nonspecific changes in drug metabolism
Question 1/1
3 point
Inhibition of P-glycoprotein by a drug such as quinidine may lead to:
Question options:
Decreased therapeutic levels of quinidine
Increased therapeutic levels of quinidine
Decreased levels of a coadministered drug, such as digoxin, that requires
Pglycoprotein for absorption and elimination
Increased levels of a coadministered drug, such as digoxin, that requires
Pglycoprotein for absorption and elimination
Question 1/1
4 point
Warfarin resistance may be seen in patients with VCORC1 mutation,
leading to: Question options:
Toxic levels of warfarin building up
Decreased response to warfarin
Increased risk for significant drug interactions with warfarin
Less risk of drug interactions with warfarin
Question 1/1
5 point
, Pharmacogenetic testing is required by the U.S. Food and Drug
Administration prior to prescribing:
Question options:
Erythromycin
Digoxin
Cetuximab
Rifampin
Question 1/1
6 point
Carbamazepine has a Black Box Warning recommending testing for the
HLA-B*1502 allele in patients with Asian ancestry prior to starting
therapy due to: Question options:
Decreased effectiveness of carbamazepine in treating seizures in Asian
patients with the HLA-B*1502 allele
Increased risk for drug interactions in Asian patients with the HLA-B*1502
allele
Increased risk for Stevens-Johnson syndrome in Asian patients with
HLAB*1502 Allele
Patients who have the HLA-B*1502 allele being more likely to have a
resistance to carbamazepine
Question 1/1
7 point
A genetic variation in how the metabolite of the cancer drug irinotecan SN-38
is inactivated by the body may lead to: Question options:
Decreased effectiveness of irinotecan in the treatment of cancer
Increased adverse drug reactions, such as neutropenia
Delayed metabolism of the prodrug irinotecan into the active metabolite SN38
Increased concerns for irinotecan being carcinogenic
Question 1/1
8 point
